Giacobini E, Michel J P
Department of Geriatrics, University Hospitals of Geneva, Geneva Medical School, Route de Mon-Idée, CH-1226 Thônex, Geneva.
Ann Med Interne (Paris). 1998 Jun;149(4):231-7.
Cholinesterase inhibitors (ChEI) represent the drug of choice for Alzheimer's disease treatment. They produce significant improvement on cognitive as well as non-cognitive function for a period up to one year during the first three years period following clinical onset. The magnitude of cognitive improvements is similar for different ChEI; however, differences are seen with regard to incidence and severity of side effects, incidence of drop-outs, optimal ChE inhibition, pharmacokinetics properties and mode of administration.
胆碱酯酶抑制剂（ChEI）是治疗阿尔茨海默病的首选药物。在临床发病后的头三年中，它们能在长达一年的时间里显著改善认知功能和非认知功能。不同的胆碱酯酶抑制剂在认知改善程度上相似；然而，在副作用的发生率和严重程度、停药率、最佳胆碱酯酶抑制效果、药代动力学特性及给药方式方面存在差异。
